Just when the market slowdown and summer's dog days had cast a torpor over the land, Pfizer Inc. sent a blast of cooling news across the pharmaceutical landscape, disclosing that it signed an agreement to buy Pharmacia Corp. in a $60 billion stock swap. (BioWorld Today)